Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial

AIMS: In CARMELINA®, linagliptin demonstrated cardiovascular and renal safety in patients with type 2 diabetes (T2D) with high renal and cardiovascular disease (CVD) risk. We investigated safety and efficacy of this dipeptidyl peptidase‐4 inhibitor in older participants. MATERIALS AND METHODS: Subje...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Mark E., Rosenstock, Julio, Kadowaki, Takashi, Seino, Yutaka, Wanner, Christoph, Schnaidt, Sven, Clark, Douglas, Johansen, Odd Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317902/
https://www.ncbi.nlm.nih.gov/pubmed/32037653
http://dx.doi.org/10.1111/dom.13995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317902/
https://www.ncbi.nlm.nih.gov/pubmed/32037653
http://dx.doi.org/10.1111/dom.13995

Ejemplares similares